New drug shows promise in Late-Stage Sjogren's trial
NCT ID NCT05350072
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This phase 3 study tests whether the drug ianalumab can reduce disease activity in people with active Sjogren's syndrome. About 275 adults with the condition will receive either ianalumab or a placebo shot under the skin. The main goal is to see if the drug improves symptoms and disease scores over 48 weeks compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ianalumab (a biologic drug given as a shot under the skin)
- What this could lead to
- If it works, this could provide a new treatment option to control disease activity and improve symptoms for people with active Sjogren's syndrome.
- What could go wrong
- This is a phase 3 trial, but results are not yet available. The drug may not prove more effective than placebo, and side effects are possible with any biologic therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altoona Center for Clin Res
Duncansville, Pennsylvania, 16635, United States
-
Baylor College Of Medicine
Houston, Texas, 77030, United States
-
Carolina Arthritis Associates
Wilmington, North Carolina, 28401, United States
-
Houston Rheumatology and Arthrit
Katy, Texas, 77494, United States
-
Indiana Univ School of Dentistry
Indianapolis, Indiana, 46202, United States
-
Medvin Clinical Research
Van Nuys, California, 91405, United States
-
Metroplex Clinical Research
Dallas, Texas, 75231, United States
-
NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
-
Novartis Investigative Site
Graz, 8036, Austria
-
Novartis Investigative Site
Stockerau, 2000, Austria
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Vitória, Espírito Santo, 29055 450, Brazil
-
Novartis Investigative Site
Juiz de Fora, Minas Gerais, 36010 570, Brazil
-
Novartis Investigative Site
Ribeirão Preto, São Paulo, 14048-900, Brazil
-
Novartis Investigative Site
São Paulo, 01409-902, Brazil
-
Novartis Investigative Site
Santiago, Santiago Metropolitan, 7500571, Chile
-
Novartis Investigative Site
Santiago, Santiago Metropolitan, 7500710, Chile
-
Novartis Investigative Site
Guangzhou, Guangdong, 510630, China
-
Novartis Investigative Site
Shenzhen, Guangdong, 518020, China
-
Novartis Investigative Site
Wuhan, Hubei, 430030, China
-
Novartis Investigative Site
Baotou, Inner Mongolia, 014010, China
-
Novartis Investigative Site
Hohhot, Inner Mongolia, 010050, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110011, China
-
Novartis Investigative Site
Linyi, Shandong, 276000, China
-
Novartis Investigative Site
Taiyuan, Shanxi, 030000, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Beijing, 100050, China
-
Novartis Investigative Site
Brno, 638 00, Czechia
-
Novartis Investigative Site
Prague, 148 00, Czechia
-
Novartis Investigative Site
Uherské Hradiště, 686 01, Czechia
-
Novartis Investigative Site
Caen, 14033, France
-
Novartis Investigative Site
Dijon, 21000, France
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Marseille, 13005, France
-
Novartis Investigative Site
Paris, 75010, France
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Saint-Priest-en-Jarez, 42270, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Würzburg, Bavaria, 97080, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Erlangen, 91056, Germany
-
Novartis Investigative Site
Gommern, 39245, Germany
-
Novartis Investigative Site
Ludwigshafen, 67063, Germany
-
Novartis Investigative Site
Guatemala City, 01009, Guatemala
-
Novartis Investigative Site
Guatemala City, 01010, Guatemala
-
Novartis Investigative Site
Guatemala City, 01011, Guatemala
-
Novartis Investigative Site
Quetzaltenango, 9001, Guatemala
-
Novartis Investigative Site
Vilnius, 08406, Lithuania
-
Novartis Investigative Site
Guadalajara, Jalisco, 44650, Mexico
-
Novartis Investigative Site
Mexico City, Mexico City, 06700, Mexico
-
Novartis Investigative Site
Wroclaw, Lower Silesian Voivodeship, 52-210, Poland
-
Novartis Investigative Site
Bydgoszcz, 85-168, Poland
-
Novartis Investigative Site
Krakow, 30-002, Poland
-
Novartis Investigative Site
Lublin, 20-090, Poland
-
Novartis Investigative Site
Braga, 4710243, Portugal
-
Novartis Investigative Site
Guarda, 6301-858, Portugal
-
Novartis Investigative Site
Lisbon, 1050-034, Portugal
-
Novartis Investigative Site
Lisbon, 1349-019, Portugal
-
Novartis Investigative Site
Lisbon, 1649-035, Portugal
-
Novartis Investigative Site
Singapore, S308433, Singapore
-
Novartis Investigative Site
Gwangju, 61469, South Korea
-
Novartis Investigative Site
Seoul, 06591, South Korea
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
Sabadell, Barcelona, 08208, Spain
-
Novartis Investigative Site
Bilbao, Bizkaia, 48013, Spain
-
Novartis Investigative Site
A Coruña, 15006, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Ankara, Bilkent Cankaya, 06800, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, Yenimahalle, 06500, Turkey (Türkiye)
-
Novartis Investigative Site
Kocaeli, 41380, Turkey (Türkiye)
-
Ochsner Health System
Baton Rouge, Louisiana, 70809, United States
-
Precision Comprehensive Research
Colleyville, Texas, 76034, United States
-
STAT Research Inc
Dayton, Ohio, 45402, United States
-
The John Hopkins Jerome L Greene Sjogren
Baltimore, Maryland, 21224, United States
-
West Broward Rheumatology Associates Inc
Tamarac, Florida, 33321, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye drops aim to calm Sjögren's dry eye by blocking inflammation
- Scientists investigate immune cell role in rare IgG4 disease
- New hope for Sjögren's fatigue: acupuncture and nerve zaps join exercise in clinical trial
- Rare disease pregnancy study pulled before it began
- New Sjögren's drug shows promise in small study
- Blood test may predict dangerous immunotherapy reactions